Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EHA 2020 | Novel epigenetic drugs and their use in myeloid malignancies

Thomas Prebet • 12 Jun 2020
EHA 2020
General Leukemia Myelodysplastic Syndromes Azacitidine Decitabine

Thomas Prebet, MD, of the Yale School of Medicine, New Haven, CT, explores novel epigenetic drugs including azacitidine, and describes their use in myeloid malignancies. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Thomas Prebet

Risk stratified analysis of CPX-351 versus 7 + 3 in older adults with AML 3:31
Risk stratified analysis of CPX-351 versus 7 + 3 in older adults with AML
Thomas Prebet • 18 Nov 2020
Hypomethylating agent based combinations in MDS 1:50
Hypomethylating agent based combinations in MDS
Thomas Prebet • 18 Nov 2020
AML: what to look forward to at ASH 2020 2:19
AML: what to look forward to at ASH 2020
Thomas Prebet • 18 Nov 2020
New treatments for AML 1:19
New treatments for AML
Thomas Prebet • 7 Oct 2020

Related Videos

The value and mission of the International Workshop on Acute Leukemias 14:36
The value and mission of the International Workshop on Acute Leukemias
Charles Craddock et al. • 21 Oct 2025
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years? 1:30
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years?
Koichi Takahashi • 26 Sep 2025
One big question with Naval Daver: what AML advance could transform frontline care in three years? 1:05
One big question with Naval Daver: what AML advance could transform frontline care in three years?
Naval Daver • 26 Sep 2025
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years? 3:13
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years?
Charles Craddock • 26 Sep 2025
The content of VJHemOnc is intended for healthcare professionals